MDST Medicsight

 

TIDMMDST 
 
RNS Number : 8324I 
Medicsight Plc 
19 March 2010 
 

 
+------------------------------+------------------------------+ 
| Press Release                | 19 March 2010                | 
+------------------------------+------------------------------+ 
 
                                 Medicsight Plc 
                        ("Medicsight" or "the Company") 
 
                                Board Appointment 
                  Troy Robinson appointed to Medicsight Board 
 
Medicsight Plc (AIM: MDST), industry leader in the development of Computer-Aided 
Detection (CAD) and image analysis software which assists in the early detection 
and diagnosis of disease, is pleased to announce that Mr Troy Robinson (aged 34) 
has been appointed to the Board as Chief Financial Officer (CFO) and Company 
Secretary with immediate effect. 
 
Troy joined Medicsight in February 2007 as Group Financial Controller after a 
successful career with IVAX pharmaceuticals and HP foods. During his tenure with 
Medicsight, Troy has played a pivotal role in both the Medicsight IPO and the 
subsequent global expansion of the finance function. Troy was appointed CFO in 
February 2009, as a non Board position, and has continued to contribute to The 
Company's success.  Troy is an associate of the Chartered Institute of 
Management Accountants and holds a Bachelor of Arts degree from Manchester 
Metropolitan University. 
 
Allan Rowley, CEO of Medicsight, commented "I am delighted to appoint Troy to 
the Board of Medicsight. He has made a significant contribution since joining 
the Company and I look forward to continuing to work with him as a member of the 
Medicsight Board." 
 
This announcement sets out the disclosures required pursuant to Schedule 2, 
paragraph (g) of the AIM Rules for Companies in respect of this appointment. 
 
Troy Robinson holds interests in 300,000 Medicsight Plc Scheme J Share Options 
awarded on 15 May 2009. Scheme J will vest in equal one-sixths every six months 
for three years following the grant date. 
 
Troy Robinson was a director of 115 Murray Road Management Company Limited 
between 2004 and 2005. 
 
                                    - ENDS - 
 
For further information: 
 
+------------------------------------+------------------------+ 
| Medicsight PLC                     | www.medicsight.com     | 
+------------------------------------+------------------------+ 
| Allan Rowley                       | +44 (0)20 7605 7950    | 
|                                    |                        | 
+------------------------------------+------------------------+ 
| Daniel Stewart & Company PLC       |                        | 
+------------------------------------+------------------------+ 
| Simon Leathers / Emma Earl         | +44 (0) 20 7776 6550   | 
+------------------------------------+------------------------+ 
Media enquiries: 
+------------------------------------+------------------------+ 
| Abchurch                           | +44 (0) 20 7398 7700   | 
+------------------------------------+------------------------+ 
| Heather Salmond / Simone Elviss /  | +44 (0) 20 7398 7728   | 
| Quincy Allan                       |                        | 
+------------------------------------+------------------------+ 
| simone.elviss@abchurch-group.com   | www.abchurch-group.com | 
+------------------------------------+------------------------+ 
 
Notes to editors 
Medicsight PLC is a UK-headquartered, research driven, leading developer of 
computer-aided detection (CAD) and image analysis software for the medical 
imaging market. The CAD software automatically highlights suspicious areas on 
computerised tomography (CT) scans of the colon and lung, helping radiologists 
to identify, measure and analyse potential disease and early indicators of 
disease. Medicsight's CAD software has been developed using one of the world's 
largest and most population diverse databases of verified patient CT scan data. 
Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly 
integrated with the advanced 3D visualisation workstations of several 
industry-leading imaging equipment partners. 
 
About Computer-Aided Detection 
With increasingly sophisticated radiological imaging hardware such as 
Multi-Detector CT scanners, radiologists are facing a growing challenge in the 
amount of detailed patient image data that they must review for each patient 
examination. Some CT scan examinations generate as many as 1000 images per 
patient. Review of this data by the radiologist is not only time-consuming but 
also prone to error due to reader fatigue. CAD software can help the reviewing 
radiologist by analysing the image data and automatically highlighting 
suspicious regions of interest for closer inspection. Without CAD software some 
potential abnormalities or areas of disease may be overlooked. This is critical 
for diagnosis and the management of patient outcomes as early detection of 
disease greatly increases the probability of successful treatment and a positive 
therapeutic outcome. 
 
About Medicsight's CAD software 
Medicsight's ColonCAD(TM) and LungCAD(TM) software use an advanced CAD algorithm 
to analyse CT scans of the colon and lung and automatically highlight suspicious 
areas that may be indicators of disease. CAD may highlight areas easily 
overlooked by the reviewing radiologist, such as small lesions or regions that 
are hidden from view behind folds in the colon or normal structures and 
surrounding tissue in the lung. 
 
Both CAD products seamlessly integrate with the advanced 3D visualisation 
platforms of industry-leading imaging equipment partners. The integrated systems 
provide sophisticated image viewing capabilities, including 3D reconstructed 
image data, with the added advantage of demonstrating automatic CAD findings to 
assist clinical end users in the detection and analysis of disease. This allows 
clinical end users to perform either a 'second read', where CAD findings are 
displayed to the user after completion of an initial review of the CT scan data, 
or a 'concurrent read' where CAD findings are displayed during the user's 
initial review of the original CT scan images. 
 
Since inception, Medicsight has developed close and lasting relationships with 
some of the world's foremost clinicians in product related areas. This provides 
the Company with a wealth of clinical expertise and dedicated clinical research 
to support ongoing product development. Medicsight also collaborates with a 
number of leading academic institutions and clinical research programmes 
worldwide to develop the Company's comprehensive database of population diverse 
verified patient CT scan data, thus allowing Medicsight's products to be 
validated to the highest possible standards. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOAKKFDQOBKDPND 
 

Medicsight (LSE:MDST)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Medicsight (LSE:MDST)
Historical Stock Chart
Von Dez 2023 bis Dez 2024